Jupiter Life Line Hospitals (JLHL) Q4 24/25 earnings summary

Executive summary

• Achieved near-term target and visibility into a 2,500-bed network in Western India, with major expansion projects in Dombivli, Pune, and Mira Road.

• Approved audited financial results for FY25 and unaudited Q4 FY25 results, with an unmodified audit opinion.

• Announced key management changes, including appointment of Dr. Ankit Thakker as Joint Managing Director and CEO, and Mr. Sivasis Sen as CFO.

• Approved amalgamation of Medulla Healthcare Private Limited to optimize costs and streamline structure.

• Infrastructure upgrades at Thane and Indore hospitals, including new beds, OTs, and expanded facilities.

Financial highlights

• FY25 consolidated revenue was ₹12,902.2 million, up from ₹10,954.8 million in FY24; EBITDA at ₹2,577.0 million, up from ₹1,954.2 million.

• FY25 PAT was ₹1,935.0 million, up from ₹1,766.1 million in FY24; PAT margin at 15.3%.

• Q4 FY25 consolidated revenue was ₹3,337.7 million, up from ₹2,994.4 million in Q4 FY24; EBITDA margin at 23.9%.

• ARPOB for FY25 was ₹60,600, up 10.4% year-on-year.

• Cash flow from operations for FY25 was ₹2,533.0 million, up from ₹1,145.2 million in FY24.

Outlook and guidance

• Dombivli hospital (500 beds) to launch in Q1FY27; Pune II (500 beds) construction to begin post-monsoon; Mira Road land acquired for a 300-bed hospital.

• Board recommended a final dividend of ₹1 per share for FY25, subject to AGM approval.

• ARPOB growth expected to align with inflation for mature hospitals; Indore may see higher growth for one more year.